A study of RC118 plus toripalimab/RC148 for advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (RC118 plus toripalimab/RC148) for people with advanced stomach or gastroesophageal junction cancer. It’s for those whose cancer has not responded to standard treatment and whose tumors have a specific protein called Claudin 18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stomach or gastroesophageal junction cancer that has spread and has not responded to at least one prior treatment.
- Your tumor must test positive for a specific protein called Claudin 18.2 (moderate to high levels).
- You should be between 18 and 75 years old and able to take care of yourself (ECOG 0 or 1).
- You must have had no more than 2 prior systemic (whole-body) cancer treatments.
- You cannot have certain serious medical conditions like uncontrolled infections, heart problems, or autoimmune diseases.
- You must agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial is testing a combination of four medicines (RC48, adebrelimab, apatinib, and S-1) as a pre-surgery treatment for people with locally advanced stomach cancer that is HER2 positive. The goal is to shrink the tumor before surgery and possibly improve outcomes.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.